Floatz logo

Mab 216

Leukemia, Lymphocytic

Steven E. Coutremonoclonal_antibodyPhase 1Dormant
CC
47/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
32/ 100
Competitive Position
95/ 100

Competitive context

13 Active assets in the Leukemia, Lymphocytic cohort.

Asset / SponsorPhaseRating
Fludarabine
Dartmouth-Hitchcock Medical Center
Phase 4BBB
Ibrutinib
Loxo Oncology, Inc.
Phase 4BBB
Busulphan
Dartmouth-Hitchcock Medical Center
Phase 4BB
Pirtobrutinib
Loxo Oncology, Inc.
Phase 3BB
IMMUNOGLOBULIN G 1 (HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .GAMMA.1-CHAIN ANTI-HUMAN ANTIGEN CD 20), DISULFIDE WITH HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .KAPPA.-CHAIN, DIMER
University of Washington
Phase 2BB

View all 50 →

Same molecule, other indications

Mab 216 is also rated in:

acute lymphoblastic leukemiaDormant
CC
Indicative ·
46 / 100
View asset →
leukemiaDormant
CC
Indicative ·
40 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →